Skip to main content

About the Lab

Dr. Doherty’s initial research identified novel therapeutic targets for the airway inflammation and remodeling that occur in chronic asthma pathology. The Doherty lab has since developed a focus on innate type 2 lung responses that contribute to asthma and allergic airway disease. We have identified novel mechanisms that regulate group 2 innate lymphoid cells (ILC2s) using animal models and human samples.


Funding for the Doherty lab has been provided by: 
The National Institute of Allergy and Infectious Disease (NIAID), the Veterans Affairs Medical Center (VA), the American Lung Association (ALA), the American Academy of Allergy, Asthma and Immunology (AAAAI), and UCSD CTRI.


Asthma Fellow Symposium 2024

With AstraZeneca, Scripps Clinic Allergy and UCSD asthma fellow presentations.